首页 > 最新文献

CVIR Endovascular最新文献

英文 中文
Outcome evaluation for the treatment of low flow venous and lymphatic malformations.
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-29 DOI: 10.1186/s42155-024-00493-z
R M Moussa, A O Oseni, S Patel, L Mailli, R Morgan, L A Ratnam

Purpose: To propose a standardized method of subjectively and objectively evaluating outcomes of sclerotherapy in treating low flow vascular malformations.

Materials and methods: Sixty-six patients with low flow vascular malformations (venous, lymphatic, or combined) were treated with percutaneous sclerotherapy using bleomycin, doxycycline, or sodium tetradecyl sulphate. Each lesion required between 2-5 sessions of sclerotherapy with 8-week intervals in between. The success of sclerotherapy was evaluated subjectively and objectively. The subjective response was based on the degree of patient satisfaction, by recording improvement of their symptoms and quality of life. The objective response was based on the changes in lesion characteristics after treatment, by recording changes in size, sonographic features, number of cystic spaces, and development of phleboliths.

Results: 91% of our patients were satisfied with the treatment and reported improvement of symptoms and quality of life. Radiologically, 62% (41/66) of the patients had a reduction in lesion size, 77% (51/66) had a change in echogenicity, 84% (51/61) had a reduction in cystic spaces, and 68% (30/44) developed phleboliths. Of the patients reporting significant improvement, 94% displayed reduction in cystic spaces, 89% displayed change in the echogenicity and 71% showed changes in the size of the lesions, representing a linear correlation.

Conclusion: Evaluating the outcomes of percutaneous sclerotherapy for treating vascular malformations is a recognized challenge. Creating a questionnaire with defined parameters to apply before and after treatment allows objective measurement of outcomes. This will enable improved treatment pathways and treatment choice for patients, informed consent, and enable outcome comparison with other centers.

{"title":"Outcome evaluation for the treatment of low flow venous and lymphatic malformations.","authors":"R M Moussa, A O Oseni, S Patel, L Mailli, R Morgan, L A Ratnam","doi":"10.1186/s42155-024-00493-z","DOIUrl":"10.1186/s42155-024-00493-z","url":null,"abstract":"<p><strong>Purpose: </strong>To propose a standardized method of subjectively and objectively evaluating outcomes of sclerotherapy in treating low flow vascular malformations.</p><p><strong>Materials and methods: </strong>Sixty-six patients with low flow vascular malformations (venous, lymphatic, or combined) were treated with percutaneous sclerotherapy using bleomycin, doxycycline, or sodium tetradecyl sulphate. Each lesion required between 2-5 sessions of sclerotherapy with 8-week intervals in between. The success of sclerotherapy was evaluated subjectively and objectively. The subjective response was based on the degree of patient satisfaction, by recording improvement of their symptoms and quality of life. The objective response was based on the changes in lesion characteristics after treatment, by recording changes in size, sonographic features, number of cystic spaces, and development of phleboliths.</p><p><strong>Results: </strong>91% of our patients were satisfied with the treatment and reported improvement of symptoms and quality of life. Radiologically, 62% (41/66) of the patients had a reduction in lesion size, 77% (51/66) had a change in echogenicity, 84% (51/61) had a reduction in cystic spaces, and 68% (30/44) developed phleboliths. Of the patients reporting significant improvement, 94% displayed reduction in cystic spaces, 89% displayed change in the echogenicity and 71% showed changes in the size of the lesions, representing a linear correlation.</p><p><strong>Conclusion: </strong>Evaluating the outcomes of percutaneous sclerotherapy for treating vascular malformations is a recognized challenge. Creating a questionnaire with defined parameters to apply before and after treatment allows objective measurement of outcomes. This will enable improved treatment pathways and treatment choice for patients, informed consent, and enable outcome comparison with other centers.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"84"},"PeriodicalIF":1.2,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large language model doctor: assessing the ability of ChatGPT-4 to deliver interventional radiology procedural information to patients during the consent process.
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-29 DOI: 10.1186/s42155-024-00477-z
Hayden L Hofmann, Jenanan Vairavamurthy

Purpose: The study aims to evaluate how current interventional radiologists view ChatGPT in the context of informed consent for interventional radiology (IR) procedures.

Methods: ChatGPT-4 was instructed to outline the risks, benefits, and alternatives for IR procedures. The outputs were reviewed by IR physicians to assess if outputs were 1) accurate, 2) comprehensive, 3) easy to understand, 4) written in a conversational tone, and 5) if they were comfortable providing the output to the patient. For each criterion, outputs were measured on a 5-point scale. Mean scores and percentage of physicians rating output as sufficient (4 or 5 on 5-point scale) were measured. A linear regression correlated mean rating with number of years in practice. Intraclass correlation coefficient (ICC) measured agreement among physicians.

Results: The mean rating of the ChatGPT responses was 4.29, 3.85, 4.15, 4.24, 3.82 for accuracy, comprehensiveness, readability, conversational tone, and physician comfort level, respectively. Percentage of physicians rating outputs as sufficient was 84%, 71%, 85%, 85%, and 67% for accuracy, comprehensiveness, readability, conversational tone, and physician comfort level, respectively. There was an inverse relationship between years in training and output score (coeff = -0.03413, p = 0.0128); ICC measured 0.39 (p = 0.003).

Conclusions: GPT-4 produced outputs that were accurate, understandable, and in a conversational tone. However, GPT-4 had a decreased capacity to produce a comprehensive output leading some physicians to be uncomfortable providing the output to patients. Practicing IRs should be aware of these limitations when counseling patients as ChatGPT-4 continues to develop into a clinically usable AI tool.

{"title":"Large language model doctor: assessing the ability of ChatGPT-4 to deliver interventional radiology procedural information to patients during the consent process.","authors":"Hayden L Hofmann, Jenanan Vairavamurthy","doi":"10.1186/s42155-024-00477-z","DOIUrl":"10.1186/s42155-024-00477-z","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to evaluate how current interventional radiologists view ChatGPT in the context of informed consent for interventional radiology (IR) procedures.</p><p><strong>Methods: </strong>ChatGPT-4 was instructed to outline the risks, benefits, and alternatives for IR procedures. The outputs were reviewed by IR physicians to assess if outputs were 1) accurate, 2) comprehensive, 3) easy to understand, 4) written in a conversational tone, and 5) if they were comfortable providing the output to the patient. For each criterion, outputs were measured on a 5-point scale. Mean scores and percentage of physicians rating output as sufficient (4 or 5 on 5-point scale) were measured. A linear regression correlated mean rating with number of years in practice. Intraclass correlation coefficient (ICC) measured agreement among physicians.</p><p><strong>Results: </strong>The mean rating of the ChatGPT responses was 4.29, 3.85, 4.15, 4.24, 3.82 for accuracy, comprehensiveness, readability, conversational tone, and physician comfort level, respectively. Percentage of physicians rating outputs as sufficient was 84%, 71%, 85%, 85%, and 67% for accuracy, comprehensiveness, readability, conversational tone, and physician comfort level, respectively. There was an inverse relationship between years in training and output score (coeff = -0.03413, p = 0.0128); ICC measured 0.39 (p = 0.003).</p><p><strong>Conclusions: </strong>GPT-4 produced outputs that were accurate, understandable, and in a conversational tone. However, GPT-4 had a decreased capacity to produce a comprehensive output leading some physicians to be uncomfortable providing the output to patients. Practicing IRs should be aware of these limitations when counseling patients as ChatGPT-4 continues to develop into a clinically usable AI tool.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"83"},"PeriodicalIF":1.2,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endovascular treatment of lower limb acute DVT: current trends and future directions. 下肢急性深静脉血栓的血管内治疗:当前趋势和未来方向。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-26 DOI: 10.1186/s42155-024-00495-x
Francesco Siciliano, Edoardo Ronconi, Tommaso Rossi, Federica Fanelli, Miltiadis Krokidis, Pasqualino Sirignano, Michele Rossi, Marcello Andrea Tipaldi

AIM OF THE STUDY: This systematic review aims to evaluate the efficacy, safety, and comparative outcomes of endovascular treatments for acute lower limb deep vein thrombosis (DVT), including catheter-directed thrombolysis (CDT), pharmacomechanical thrombectomy (PMT), mechanical thrombectomy, and venous stenting, drawing insights from a diverse range of studies.

Materials and methods: A comprehensive literature search identified 33 relevant studies, including randomized controlled trials, cohort studies, systematic reviews, and case reports. Data extraction focused on study design, intervention type, outcome measures, and follow-up duration.

Results: Catheter-directed thrombolysis demonstrates promising results in enhancing venous patency and reducing post-thrombotic syndrome, with careful patient selection being crucial. Pharmacomechanical and mechanical thrombectomy devices offer immediate and long-term benefits, emphasizing individualized patient care. Venous stenting serves as a crucial adjunctive therapy, particularly in cases of residual venous obstruction, though further research is needed for optimal patient selection and long-term outcomes. Timing and selection of endovascular interventions remain critical considerations, necessitating multidisciplinary approaches and ongoing research.

Conclusion: This review provides valuable insights for clinicians and researchers, guiding evidence-based decision-making and shaping future research directions in the dynamic field of endovascular interventions for acute lower limb DVT.

研究目的:本系统综述旨在评估急性下肢深静脉血栓(DVT)血管内治疗的有效性、安全性和比较结果,包括导管引导溶栓(CDT)、药物机械血栓切除术(PMT)、机械血栓切除术和静脉支架置入术,从各种研究中汲取启示:通过全面的文献检索确定了 33 项相关研究,包括随机对照试验、队列研究、系统综述和病例报告。数据提取的重点是研究设计、干预类型、结果测量和随访时间:结果:导管引导溶栓在提高静脉通畅性和减少血栓后综合征方面取得了可喜的成果,但谨慎选择患者至关重要。药物机械和机械血栓清除装置可提供直接和长期的益处,强调对患者的个体化护理。静脉支架植入术是一种重要的辅助疗法,尤其适用于残余静脉阻塞的病例,但如何选择最佳患者和取得长期疗效仍需进一步研究。血管内介入治疗的时机和选择仍是关键因素,需要多学科方法和持续研究:本综述为临床医生和研究人员提供了有价值的见解,为基于证据的决策提供了指导,并为急性下肢深静脉血栓的血管内介入这一充满活力的领域确定了未来的研究方向。
{"title":"Endovascular treatment of lower limb acute DVT: current trends and future directions.","authors":"Francesco Siciliano, Edoardo Ronconi, Tommaso Rossi, Federica Fanelli, Miltiadis Krokidis, Pasqualino Sirignano, Michele Rossi, Marcello Andrea Tipaldi","doi":"10.1186/s42155-024-00495-x","DOIUrl":"10.1186/s42155-024-00495-x","url":null,"abstract":"<p><p>AIM OF THE STUDY: This systematic review aims to evaluate the efficacy, safety, and comparative outcomes of endovascular treatments for acute lower limb deep vein thrombosis (DVT), including catheter-directed thrombolysis (CDT), pharmacomechanical thrombectomy (PMT), mechanical thrombectomy, and venous stenting, drawing insights from a diverse range of studies.</p><p><strong>Materials and methods: </strong>A comprehensive literature search identified 33 relevant studies, including randomized controlled trials, cohort studies, systematic reviews, and case reports. Data extraction focused on study design, intervention type, outcome measures, and follow-up duration.</p><p><strong>Results: </strong>Catheter-directed thrombolysis demonstrates promising results in enhancing venous patency and reducing post-thrombotic syndrome, with careful patient selection being crucial. Pharmacomechanical and mechanical thrombectomy devices offer immediate and long-term benefits, emphasizing individualized patient care. Venous stenting serves as a crucial adjunctive therapy, particularly in cases of residual venous obstruction, though further research is needed for optimal patient selection and long-term outcomes. Timing and selection of endovascular interventions remain critical considerations, necessitating multidisciplinary approaches and ongoing research.</p><p><strong>Conclusion: </strong>This review provides valuable insights for clinicians and researchers, guiding evidence-based decision-making and shaping future research directions in the dynamic field of endovascular interventions for acute lower limb DVT.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"82"},"PeriodicalIF":1.2,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous thrombectomy using the InThrill Thrombectomy System: preliminary experiences. 使用 InThrill 血栓切除系统进行静脉血栓切除术:初步经验。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-23 DOI: 10.1186/s42155-024-00498-8
Kevin M McElroy, David S Shin, Matthew Abad-Santos, Eric J Monroe, Jeffrey Forris Beecham Chick
{"title":"Venous thrombectomy using the InThrill Thrombectomy System: preliminary experiences.","authors":"Kevin M McElroy, David S Shin, Matthew Abad-Santos, Eric J Monroe, Jeffrey Forris Beecham Chick","doi":"10.1186/s42155-024-00498-8","DOIUrl":"10.1186/s42155-024-00498-8","url":null,"abstract":"","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"80"},"PeriodicalIF":1.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes. 门静脉慢性全闭塞的经皮治疗:技术方面和疗效的回顾性分析。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-23 DOI: 10.1186/s42155-024-00496-w
Ludovico Dulcetta, Paolo Marra, Riccardo Muglia, Francesco Saverio Carbone, Mauro Viganò, Angelo Di Giorgio, Lorenzo D'Antiga, Stefano Fagiuoli, Sandro Sironi

Background: Chronic total occlusion (CTO) of the portal vein is one of the main causes of portal hypertension, which may result in life-threatening complications often managed by interventional radiology (IR). The aim of this study is to report the innovative experience with percutaneous revascularization therapy in the management of portal vein CTO in paediatric and adult patients.

Materials and methods: From January 2020 to December 2023 consecutive paediatric and adult patients with severe portal hypertension resulting from portal vein CTO who underwent attempts at percutaneous recanalization were retrospectively reviewed. Technical aspects including the percutaneous approach, portal vein stenting, transjugular intrahepatic portosystemic shunt (TIPS) creation, varices embolization and clinical outcomes including adverse events and control of portal hypertension were analyzed. Technical success was defined as at least partial restoration of the portal vein patency at the final angiogram. Clinical success was defined as the improvement of clinical-laboratory signs of portal hypertension and control for variceal bleeding.

Results: Fifteen patients (median age = 21 years, range = 59 years; 10 males; 5 children) with portal vein CTO underwent a total of 25 percutaneous revascularization procedures. Nine patients (60%; 5 children, 4 adults) were liver transplant recipients. All patients except one had cavernous transformation of the extra-hepatic portal vein, involving the spleno-mesenteric confluence in 5 cases. Technical success was achieved in 13/15 (87%) patients of whom 8 had portal revascularization through the placement of an extra-hepatic stent; indeed, in six cases, a TIPS was performed to achieve sustained portal vein patency. Embolization of varices and/or cavernoma was performed in 12 patients. Adverse events occurred in 2/15 (splenic artery perforation and hemoperitoneum, one each) managed without sequelae. Technical success led to clinical success in all the 13/15 (87%) cases, with a median follow-up of 20 months (IQR 4-34 months).

Conclusion: CTO can be managed effectively by interventional radiology. Restored portal flow physiology alone is possible in most patients, while TIPS may be required in a small proportion of them, to prolong portal vein patency and control portal hypertension.

背景:门静脉慢性全闭塞(CTO)是门静脉高压症的主要病因之一,可能导致危及生命的并发症,通常由介入放射学(IR)处理。本研究旨在报告经皮血管重建疗法在治疗儿童和成人门静脉CTO方面的创新经验:回顾性审查了 2020 年 1 月至 2023 年 12 月期间连续接受经皮再通尝试的门静脉 CTO 导致严重门静脉高压的儿童和成人患者。分析了包括经皮方法、门静脉支架植入术、经颈静脉肝内门体分流术(TIPS)、静脉曲张栓塞术在内的技术方面以及包括不良事件和门静脉高压控制在内的临床结果。技术成功的定义是在最终血管造影时门静脉至少部分恢复通畅。临床成功的定义是门静脉高压的临床-实验室体征得到改善,静脉曲张出血得到控制:15名门静脉CTO患者(中位年龄=21岁,范围=59岁;10名男性;5名儿童)共接受了25例经皮血管重建手术。9名患者(60%;5名儿童,4名成人)是肝移植受者。除一名患者外,所有患者的肝外门静脉都发生了海绵状转变,其中 5 例涉及脾门-肠门汇合处。13/15(87%)例患者获得了技术上的成功,其中8例通过放置肝外支架实现了门静脉血管再通;实际上,有6例患者通过TIPS实现了门静脉的持续通畅。12名患者接受了静脉曲张和/或海绵状瘤栓塞术。2/15的患者发生了不良事件(脾动脉穿孔和血性腹膜炎各1例),经处理后未留下后遗症。13/15(87%)例患者均因技术成功而获得临床成功,中位随访时间为20个月(IQR 4-34个月):结论:介入放射学可有效控制 CTO。结论:介入放射学可有效处理 CTO,大多数患者可单独恢复门静脉血流生理功能,而小部分患者可能需要 TIPS,以延长门静脉通畅时间并控制门静脉高压。
{"title":"Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes.","authors":"Ludovico Dulcetta, Paolo Marra, Riccardo Muglia, Francesco Saverio Carbone, Mauro Viganò, Angelo Di Giorgio, Lorenzo D'Antiga, Stefano Fagiuoli, Sandro Sironi","doi":"10.1186/s42155-024-00496-w","DOIUrl":"10.1186/s42155-024-00496-w","url":null,"abstract":"<p><strong>Background: </strong>Chronic total occlusion (CTO) of the portal vein is one of the main causes of portal hypertension, which may result in life-threatening complications often managed by interventional radiology (IR). The aim of this study is to report the innovative experience with percutaneous revascularization therapy in the management of portal vein CTO in paediatric and adult patients.</p><p><strong>Materials and methods: </strong>From January 2020 to December 2023 consecutive paediatric and adult patients with severe portal hypertension resulting from portal vein CTO who underwent attempts at percutaneous recanalization were retrospectively reviewed. Technical aspects including the percutaneous approach, portal vein stenting, transjugular intrahepatic portosystemic shunt (TIPS) creation, varices embolization and clinical outcomes including adverse events and control of portal hypertension were analyzed. Technical success was defined as at least partial restoration of the portal vein patency at the final angiogram. Clinical success was defined as the improvement of clinical-laboratory signs of portal hypertension and control for variceal bleeding.</p><p><strong>Results: </strong>Fifteen patients (median age = 21 years, range = 59 years; 10 males; 5 children) with portal vein CTO underwent a total of 25 percutaneous revascularization procedures. Nine patients (60%; 5 children, 4 adults) were liver transplant recipients. All patients except one had cavernous transformation of the extra-hepatic portal vein, involving the spleno-mesenteric confluence in 5 cases. Technical success was achieved in 13/15 (87%) patients of whom 8 had portal revascularization through the placement of an extra-hepatic stent; indeed, in six cases, a TIPS was performed to achieve sustained portal vein patency. Embolization of varices and/or cavernoma was performed in 12 patients. Adverse events occurred in 2/15 (splenic artery perforation and hemoperitoneum, one each) managed without sequelae. Technical success led to clinical success in all the 13/15 (87%) cases, with a median follow-up of 20 months (IQR 4-34 months).</p><p><strong>Conclusion: </strong>CTO can be managed effectively by interventional radiology. Restored portal flow physiology alone is possible in most patients, while TIPS may be required in a small proportion of them, to prolong portal vein patency and control portal hypertension.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"81"},"PeriodicalIF":1.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Organ-preserving embolization of a giant splenic hemangioma in an adult. 成人巨大脾脏血管瘤的保全器官栓塞术。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-08 DOI: 10.1186/s42155-024-00491-1
Manos Siderakis, Stamatia Dodoura, George Gkeneralis, Viktoria Kartsouni, Myrsini Gkeli

Splenic hemangioma is a rare benign tumor, often found incidentally. Large hemangiomas bear a high risk of spontaneous rupture, an acute condition often life-threatening that requires immediate intervention. The spleen's vital role in immunity and blood filtration mandates organ-preserving management of conditions such as hypersplenism or large lesions such as hemangiomas. A 51-year-old patient was referred to our department for abdominal pain due to a giant spleen hemangioma (6,6 × 6,3 × 5,6) cm in size. The patient was treated with hemangioma embolization through the splenic artery branches that fed the lesion, without any complications. Two years post-embolization the patient mentioned no symptoms and the hemangioma was measured (3 × 2) cm.Background The patient was referred to our department due to the large size of the lesion and the patient's preference to avoid surgery and maintain the spleen. Our case report aims to underline (a) the safety and feasibility of the protocol among interventional radiologists, surgeons, and patients, (b) the benefit of relieving symptoms without losing a vital organ, and (c) the lower complication rate and hospital days compared with surgery. There are few reported cases of embolization of large spleen hemangioma. While Choi et al. (BMC Pediatr. 2018 12;18(1):354) report a similar case in a child. This case report describes the procedure in a stable adult and provides a 2-year follow-up.

脾脏血管瘤是一种罕见的良性肿瘤,通常是偶然发现的。大的血管瘤自发破裂的风险很高,这种急性病往往危及生命,需要立即干预。脾脏在免疫和血液过滤方面起着至关重要的作用,因此在处理脾功能亢进或巨大病变(如血管瘤)时必须保留器官。一名 51 岁的患者因巨大脾脏血管瘤(6.6 × 6.3 × 5.6)厘米大小的腹痛转诊至我科。患者接受了通过病变脾动脉分支进行的血管瘤栓塞治疗,未出现任何并发症。栓塞术后两年,患者未提及任何症状,血管瘤的测量值为(3 × 2)厘米。背景该患者因病灶巨大,且患者希望避免手术并保留脾脏而被转诊至我科。我们的病例报告旨在强调:(a) 该方案在介入放射科医生、外科医生和患者中的安全性和可行性;(b) 在不失去重要器官的情况下缓解症状的益处;(c) 与手术相比,并发症发生率和住院天数较低。关于大脾血管瘤栓塞治疗的报道很少。而 Choi 等人(BMC Pediatr. 2018 12;18(1):354)报道了一例类似的儿童病例。本病例报告描述了在一名病情稳定的成年人身上进行的手术,并提供了 2 年的随访。
{"title":"Organ-preserving embolization of a giant splenic hemangioma in an adult.","authors":"Manos Siderakis, Stamatia Dodoura, George Gkeneralis, Viktoria Kartsouni, Myrsini Gkeli","doi":"10.1186/s42155-024-00491-1","DOIUrl":"10.1186/s42155-024-00491-1","url":null,"abstract":"<p><p>Splenic hemangioma is a rare benign tumor, often found incidentally. Large hemangiomas bear a high risk of spontaneous rupture, an acute condition often life-threatening that requires immediate intervention. The spleen's vital role in immunity and blood filtration mandates organ-preserving management of conditions such as hypersplenism or large lesions such as hemangiomas. A 51-year-old patient was referred to our department for abdominal pain due to a giant spleen hemangioma (6,6 × 6,3 × 5,6) cm in size. The patient was treated with hemangioma embolization through the splenic artery branches that fed the lesion, without any complications. Two years post-embolization the patient mentioned no symptoms and the hemangioma was measured (3 × 2) cm.Background The patient was referred to our department due to the large size of the lesion and the patient's preference to avoid surgery and maintain the spleen. Our case report aims to underline (a) the safety and feasibility of the protocol among interventional radiologists, surgeons, and patients, (b) the benefit of relieving symptoms without losing a vital organ, and (c) the lower complication rate and hospital days compared with surgery. There are few reported cases of embolization of large spleen hemangioma. While Choi et al. (BMC Pediatr. 2018 12;18(1):354) report a similar case in a child. This case report describes the procedure in a stable adult and provides a 2-year follow-up.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"79"},"PeriodicalIF":1.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel conformable embolic for selective transarterial embolization of acute hemorrhages: a technical note. 用于选择性经动脉栓塞急性出血的新型保形栓塞器:技术说明。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-06 DOI: 10.1186/s42155-024-00492-0
Qian Yu, Osman Ahmed, Jiaqi Chen, Yousuf Islam, Brian Funaki, Mikin Patel

Background: Obsidio conformable embolic (OCE, Boston Scientific, MA) is a novel, radiopaque and conformable embolic. The purpose of this report is to describe its use for treatment of acute intra-abdominal hemorrhages.

Methods and results: Three patients presented with acute hemorrhage and were treated with OCE, including post-paracentesis hemorrhage, penetrating trauma to the liver, and blunt trauma in the spleen. All cases were performed under moderate sedation, with hemostasis achieved by end of procedure using less than 1 vial of OCE (0.2-0.4 ml). No severe adverse events occurred. None required repeated treatment.

Short conclusion: OCE is a safe and effective embolic agent for treatment of intra-abdominal or visceral hemorrhage. Future studies with larger sample sizes and longer follow-up are warranted.

背景:Obsidio适形栓塞(OCE,波士顿科学公司,马萨诸塞州)是一种新型的、不透射线的适形栓塞。本报告旨在描述其在治疗急性腹腔内出血中的应用:三名急性出血患者接受了 OCE 治疗,包括腹腔穿刺术后出血、肝脏穿透性创伤和脾脏钝性创伤。所有病例都是在中度镇静的情况下进行的,手术结束时用了不到 1 瓶 OCE(0.2-0.4 毫升)就实现了止血。无严重不良事件发生。简短结论简短结论:OCE是治疗腹腔或内脏出血的一种安全有效的栓塞剂。今后有必要进行样本量更大、随访时间更长的研究。
{"title":"A novel conformable embolic for selective transarterial embolization of acute hemorrhages: a technical note.","authors":"Qian Yu, Osman Ahmed, Jiaqi Chen, Yousuf Islam, Brian Funaki, Mikin Patel","doi":"10.1186/s42155-024-00492-0","DOIUrl":"10.1186/s42155-024-00492-0","url":null,"abstract":"<p><strong>Background: </strong>Obsidio conformable embolic (OCE, Boston Scientific, MA) is a novel, radiopaque and conformable embolic. The purpose of this report is to describe its use for treatment of acute intra-abdominal hemorrhages.</p><p><strong>Methods and results: </strong>Three patients presented with acute hemorrhage and were treated with OCE, including post-paracentesis hemorrhage, penetrating trauma to the liver, and blunt trauma in the spleen. All cases were performed under moderate sedation, with hemostasis achieved by end of procedure using less than 1 vial of OCE (0.2-0.4 ml). No severe adverse events occurred. None required repeated treatment.</p><p><strong>Short conclusion: </strong>OCE is a safe and effective embolic agent for treatment of intra-abdominal or visceral hemorrhage. Future studies with larger sample sizes and longer follow-up are warranted.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"78"},"PeriodicalIF":1.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of the needle rendezvous technique for infrainguinal arterial calcified lesions. 针会合技术治疗腹股沟下动脉钙化病变的有效性和安全性。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 DOI: 10.1186/s42155-024-00490-2
Takuya Haraguchi, Masanaga Tsujimoto, Yoshifumi Kashima, Yuhei Kasai, Katsuhiko Sato, Tsutomu Fujita

Background: Lower extremity artery disease is increasingly prevalent, and complex lesions such as calcified chronic total occlusions pose significant challenges during endovascular therapy. The needle rendezvous technique, which involves puncturing a needle toward the guidewire within the lesion or lumen and advancing the guidewire into the needle lumen to achieve guidewire externalization, offers a potential solution. If device passage remains challenging, the Rendezvous-PIERCE technique can be subsequently employed by advancing the needle over the externalized guidewire to modify the lesion directly. This study aimed to evaluate the procedural outcomes of needle rendezvous in infrainguinal arterial occlusive lesions.

Methods: This single-center, retrospective, single-arm study included patients treated with needle rendezvous between August 2020 and March 2024. The primary outcome was technical success rate, defined as the device passage following guidewire externalization using needle rendezvous. Secondary outcomes included the rates of procedural success, complications, and 30-day clinical-driven target lesion revascularization (CDTLR).

Results: Twenty-five patients (25 limbs) with 52% on hemodialysis and 80% having chronic limb-threatening ischemia in 52% and 80% were enrolled. All cases involved bilateral calcified occlusions, and 72% targeted the infrapopliteal artery segment. The average needle rendezvous time was 3.7 ± 2.0 min. Rendezvous-PIERCE was performed in 28% of cases. All cases achieved 100% technical and procedural success, with no procedure-related complications. The 30-day CDTLR rate was 8%, limited to below-the-knee lesions.

Conclusions: Needle rendezvous is a safe and effective technique for treating complex infrainguinal arterial occlusions, providing a viable alternative when conventional methods fail.

背景:下肢动脉疾病越来越普遍,钙化慢性全闭塞等复杂病变给血管内治疗带来了巨大挑战。针头会合技术提供了一种潜在的解决方案,即在病变或管腔内朝导丝方向穿刺针头,并将导丝推进针腔以实现导丝外置。如果装置通过仍有困难,则可随后采用 Rendezvous-PIERCE 技术,将穿刺针推进到外置导丝上方,直接改变病变部位。本研究旨在评估在腹股沟下动脉闭塞病变中使用针头会合的手术效果:这项单中心、回顾性、单臂研究纳入了 2020 年 8 月至 2024 年 3 月间接受针式交会治疗的患者。主要结果是技术成功率,即使用针式交会器将导丝外置后设备通过率。次要结果包括手术成功率、并发症和30天临床驱动靶病变血管再通率(CDTLR):25名患者(25条肢体)中,52%正在进行血液透析,80%患有慢性肢体缺血。所有病例均为双侧钙化性闭塞,72%的病例以膝下动脉段为目标。平均针头会合时间为 3.7 ± 2.0 分钟。28%的病例进行了会合-PIERCE。所有病例的技术和手术成功率均为 100%,无手术相关并发症。30天CDTLR率为8%,仅限于膝下病变:结论:针头交会是治疗复杂的腹股沟下动脉闭塞的一种安全有效的技术,在传统方法失败时提供了一种可行的替代方法。
{"title":"Efficacy and safety of the needle rendezvous technique for infrainguinal arterial calcified lesions.","authors":"Takuya Haraguchi, Masanaga Tsujimoto, Yoshifumi Kashima, Yuhei Kasai, Katsuhiko Sato, Tsutomu Fujita","doi":"10.1186/s42155-024-00490-2","DOIUrl":"10.1186/s42155-024-00490-2","url":null,"abstract":"<p><strong>Background: </strong>Lower extremity artery disease is increasingly prevalent, and complex lesions such as calcified chronic total occlusions pose significant challenges during endovascular therapy. The needle rendezvous technique, which involves puncturing a needle toward the guidewire within the lesion or lumen and advancing the guidewire into the needle lumen to achieve guidewire externalization, offers a potential solution. If device passage remains challenging, the Rendezvous-PIERCE technique can be subsequently employed by advancing the needle over the externalized guidewire to modify the lesion directly. This study aimed to evaluate the procedural outcomes of needle rendezvous in infrainguinal arterial occlusive lesions.</p><p><strong>Methods: </strong>This single-center, retrospective, single-arm study included patients treated with needle rendezvous between August 2020 and March 2024. The primary outcome was technical success rate, defined as the device passage following guidewire externalization using needle rendezvous. Secondary outcomes included the rates of procedural success, complications, and 30-day clinical-driven target lesion revascularization (CDTLR).</p><p><strong>Results: </strong>Twenty-five patients (25 limbs) with 52% on hemodialysis and 80% having chronic limb-threatening ischemia in 52% and 80% were enrolled. All cases involved bilateral calcified occlusions, and 72% targeted the infrapopliteal artery segment. The average needle rendezvous time was 3.7 ± 2.0 min. Rendezvous-PIERCE was performed in 28% of cases. All cases achieved 100% technical and procedural success, with no procedure-related complications. The 30-day CDTLR rate was 8%, limited to below-the-knee lesions.</p><p><strong>Conclusions: </strong>Needle rendezvous is a safe and effective technique for treating complex infrainguinal arterial occlusions, providing a viable alternative when conventional methods fail.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"77"},"PeriodicalIF":1.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of outcomes for transjugular intrahepatic portosystemic shunt creation: Viatorr versus Fluency versus a bare stent/Fluency stent combination. 经颈静脉肝内门体分流术的疗效比较:Viatorr 与 Fluency 与裸支架/Fluency 支架组合。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-18 DOI: 10.1186/s42155-024-00489-9
Weizhi Li, Mengying Liu, Sheng Guan, Pengxu Ding, Jia Yuan, Yan Zhao, Peijie Li, Fuquan Ma, Hui Xue

Purpose: To compare clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) created with the single covered-uncovered stent (Viatorr TIPS Endoprosthesis) versus covered stent (Fluency) versus a combination of covered and uncovered stent.

Materials and methods: From May 2016 and July 2019, a total of 180 liver cirrhosis patients with recurrent variceal bleeding underwent TIPS creation with single covered-uncovered stent (n = 63) or covered stent (n = 41) or a covered and uncovered stent combination (n = 76). Shunt dysfunction, rebleeding, overt hepatic encephalopathy and mortality was estimated using the Kaplan-Meier method and compared with the log-rank test.

Results: The difference of baseline characteristics among these three groups were not significant. The included patients had a median age of 51 years (IQR 43-61), and 101 (56.1%) were men. The 1-year and 2-year shunt dysfunction rates were 1.6% and 3.2% in the single covered-uncovered stent group, 7.3% and 7.3% in the covered stent group and 5.3% and 6.6% in the combination group, respectively. There was no significant difference among groups [Hazard Ratio (HR) (95%CI): 1 vs 2.29 (0.38 - 13.72) vs 2.10 (0.41 - 10.83); P = 0.913]. No significant differences in the incidence of all-cause rebleeding were observed between the groups at 1 year (Viatorr vs Fluency vs combination: 11.1% vs 17.1% vs 10.5%) as well as 2 years (15.9% vs 17.1% vs 11.8%), with the HR (95%CI) being 1 vs 1.27 (0.5-3.21) vs 0.74 (0.30-1.82); P = 0.475). The 1-year and 2-year incidence of overt hepatic encephalopathy were 30.2% and 30.2% in the single covered-uncovered stent group, 22.0% and 22.0% in the covered stent group and 25.0% and 25.0% in the combination group, respectively. However, there was no significant difference among these three groups (P = 0.402). In addition, there was no significant difference in the 1-year and 2-year mortality (6.3% and 7.9% vs. 4.9% and 9.8% vs. 6.6% and 9.2%, P = 0.606).

Conclusion: No significant difference was observed among different stent groups. Fluency covered stent and the generic bare stent/Fluency covered stent was not an unreasonable alternative to the Viatorr stent for TIPS creation.

目的:比较使用单一有盖无盖支架(Viatorr TIPS Endoprosthesis)与有盖支架(Fluency)以及有盖和无盖支架组合创建经颈静脉肝内门体分流术(TIPS)的临床疗效:2016年5月至2019年7月,共有180名复发性静脉曲张出血的肝硬化患者接受了TIPS造影术,使用单一有盖无盖支架(n = 63)或有盖支架(n = 41)或有盖无盖支架组合(n = 76)。分流功能障碍、再出血、明显肝性脑病和死亡率采用卡普兰-梅耶法进行估计,并用对数秩检验进行比较:三组患者的基线特征差异不大。纳入患者的中位年龄为 51 岁(IQR 43-61),男性 101 人(56.1%)。1年和2年分流功能障碍率分别为:单一覆盖支架组1.6%和3.2%,覆盖支架组7.3%和7.3%,联合支架组5.3%和6.6%。各组间无明显差异[危险比(HR)(95%CI):1 vs 2.29 (0.38 - 13.72) vs 2.10 (0.41 - 10.83);P = 0.913]。1年时(Viatorr vs Fluency vs 组合:11.1% vs 17.1% vs 10.5%)和2年时(15.9% vs 17.1% vs 11.8%),各组间全因再出血发生率无明显差异,HR(95%CI)为1 vs 1.27 (0.5-3.21) vs 0.74 (0.30-1.82); P = 0.475)。1年和2年明显肝性脑病的发生率分别为:单一覆盖-未覆盖支架组为30.2%和30.2%,覆盖支架组为22.0%和22.0%,联合支架组为25.0%和25.0%。然而,这三组之间没有明显差异(P = 0.402)。此外,1年和2年死亡率也无明显差异(6.3%和7.9% vs. 4.9%和9.8% vs. 6.6%和9.2%,P = 0.606):结论:不同支架组之间无明显差异。Fluency覆盖支架和普通裸支架/Fluency覆盖支架在TIPS创建中并不是Viatorr支架的不合理替代品。
{"title":"Comparison of outcomes for transjugular intrahepatic portosystemic shunt creation: Viatorr versus Fluency versus a bare stent/Fluency stent combination.","authors":"Weizhi Li, Mengying Liu, Sheng Guan, Pengxu Ding, Jia Yuan, Yan Zhao, Peijie Li, Fuquan Ma, Hui Xue","doi":"10.1186/s42155-024-00489-9","DOIUrl":"https://doi.org/10.1186/s42155-024-00489-9","url":null,"abstract":"<p><strong>Purpose: </strong>To compare clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) created with the single covered-uncovered stent (Viatorr TIPS Endoprosthesis) versus covered stent (Fluency) versus a combination of covered and uncovered stent.</p><p><strong>Materials and methods: </strong>From May 2016 and July 2019, a total of 180 liver cirrhosis patients with recurrent variceal bleeding underwent TIPS creation with single covered-uncovered stent (n = 63) or covered stent (n = 41) or a covered and uncovered stent combination (n = 76). Shunt dysfunction, rebleeding, overt hepatic encephalopathy and mortality was estimated using the Kaplan-Meier method and compared with the log-rank test.</p><p><strong>Results: </strong>The difference of baseline characteristics among these three groups were not significant. The included patients had a median age of 51 years (IQR 43-61), and 101 (56.1%) were men. The 1-year and 2-year shunt dysfunction rates were 1.6% and 3.2% in the single covered-uncovered stent group, 7.3% and 7.3% in the covered stent group and 5.3% and 6.6% in the combination group, respectively. There was no significant difference among groups [Hazard Ratio (HR) (95%CI): 1 vs 2.29 (0.38 - 13.72) vs 2.10 (0.41 - 10.83); P = 0.913]. No significant differences in the incidence of all-cause rebleeding were observed between the groups at 1 year (Viatorr vs Fluency vs combination: 11.1% vs 17.1% vs 10.5%) as well as 2 years (15.9% vs 17.1% vs 11.8%), with the HR (95%CI) being 1 vs 1.27 (0.5-3.21) vs 0.74 (0.30-1.82); P = 0.475). The 1-year and 2-year incidence of overt hepatic encephalopathy were 30.2% and 30.2% in the single covered-uncovered stent group, 22.0% and 22.0% in the covered stent group and 25.0% and 25.0% in the combination group, respectively. However, there was no significant difference among these three groups (P = 0.402). In addition, there was no significant difference in the 1-year and 2-year mortality (6.3% and 7.9% vs. 4.9% and 9.8% vs. 6.6% and 9.2%, P = 0.606).</p><p><strong>Conclusion: </strong>No significant difference was observed among different stent groups. Fluency covered stent and the generic bare stent/Fluency covered stent was not an unreasonable alternative to the Viatorr stent for TIPS creation.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"76"},"PeriodicalIF":1.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142480506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The alternative for being an alternative. 另辟蹊径。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-11 DOI: 10.1186/s42155-024-00488-w
Jim A Reekers
{"title":"The alternative for being an alternative.","authors":"Jim A Reekers","doi":"10.1186/s42155-024-00488-w","DOIUrl":"10.1186/s42155-024-00488-w","url":null,"abstract":"","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"7 1","pages":"75"},"PeriodicalIF":1.2,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
CVIR Endovascular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1